Expanded Access to Upadacitinib
NCT04159597 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-01-30
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
- Crohn Disease
- Ulcerative Colitis
- Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)
- Atopic Dermatitis
Interventions
- DRUG
-
Upadacitinib
Upadacitinib will be administered as oral solution.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
NCT03345836 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
NCT02365649 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
NCT06581042 ·Status: RECRUITING
-
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
NCT07073079 ·Status: RECRUITING
-
Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA
NCT06856135 ·Status: AVAILABLE
-
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
NCT00338650 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Abatacept in Patients With Active Crohn's Disease
NCT00406653 ·Status: TERMINATED ·Phase: PHASE3
-
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
NCT06023030 ·Status: RECRUITING
-
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
NCT00055523 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Abatacept in Patients With Active Ulcerative Colitis
NCT00410410 ·Status: COMPLETED ·Phase: PHASE3
-
An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease
NCT03362736 ·Status: NO_LONGER_AVAILABLE
-
Fluorescence Imaging of IBD and RA Using Adalimumab-800CW
NCT03938701 ·Status: RECRUITING ·Phase: PHASE2
-
Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
NCT02738125 ·Status: COMPLETED
-
Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease
NCT07258641 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
NCT01861249 ·Status: TERMINATED ·Phase: PHASE2
-
Remission in Subjects With Crohn's Disease, 1 Year Phase
NCT00055497 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
NCT02782663 ·Status: COMPLETED ·Phase: PHASE2
-
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
NCT02148718 ·Status: COMPLETED ·Phase: PHASE4
-
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
NCT02451839 ·Status: COMPLETED
-
Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis
NCT01494857 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT02819635 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
NCT03606499 ·Status: COMPLETED
-
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
NCT00427921 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis
NCT01659138 ·Status: TERMINATED ·Phase: PHASE2